Current Report Filing (8-k)
01 May 2017 - 8:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): May 1, 2017
NEUROTROPE, INC.
(Exact name of registrant as specified
in its charter)
Nevada
|
000-55275
|
46-3522381
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
205 East 42
nd
Street,
16
th
Floor
New York, New York 10017
(Address of principal executive offices and zip code)
Registrant’s telephone number,
including area code: (973) 242-0005
_____________________________________________________________________________________
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General
Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company.
¨
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
¨
On May 1, 2017, Neurotrope, Inc. (the “Company”)
issued a press release announcing positive top-line results from its Phase 2 study (-202 Study) of Bryostatin-1 in patients with
moderate to severe Alzheimer’s disease (AD). A copy of the press release is attached as Exhibit 99.1 to this report and is
incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
|
|
Exhibit Number
|
|
Description of Exhibits
|
99.1
|
|
Press release of Neurotrope, Inc., dated May 1, 2017.
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
NEUROTROPE, INC.
|
|
|
|
Date: May 1, 2017
|
By: /s/ Robert Weinstein
|
|
Name:
|
Robert Weinstein
|
|
Title:
|
Chief Financial Officer, Executive Vice President, Secretary and Treasurer
|
NextTrip (NASDAQ:NTRP)
Historical Stock Chart
From Apr 2024 to May 2024
NextTrip (NASDAQ:NTRP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about NextTrip Inc (NASDAQ): 0 recent articles
More Neurotrope, Inc. News Articles